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ABSTRACT 
 
Gemcitabine shows a marked anti-tumor effect as a result of its cytotoxic action 
toward proliferative cells. In this article we aim to investigate the potential anti-tumor 
and anti-angiogenic effect of Gemcitabine following a metronomic schedule, that 
involves the regular administration of cytotoxic drugs at doses lower than standard 
treatment. In vitro results showed that human endothelial cells are more sensitive to 
Gemcitabine (IC50 3 nM) than pancreatic tumor cells (IC50 20 nM). For in vivo studies 
we used an orthotopic implantation model of human pancreatic carcinoma in nude mice. 
Gemcitabine was administered intra-peritoneally following a low-dose schedule (1 
mg/Kg/day for a month) compared with the conventional schedule (100 mg/Kg days 0, 
3, 6 and 9 post-implantation). Metronomic treatment effect on established tumor was 
equivalent to standard administration. Measure of CD31 endothelial marked area 
allowed us to demonstrate an in vivo anti-angiogenic effect of this drug that was further 
enhanced when using metronomic administration. This effect correlated with an 
induction of thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis. Our results 
allow us to hypothesize that, in addition to a direct anti-proliferative or cytotoxic anti-
endothelial cell effect, a secondary effect involving TSP-1 induction might provide an 
explanation for the specificity of the effects of metronomic gemcitabine treatment. 
 
205 words 
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INTRODUCTION 
 
Adenocarcinoma of the exocrine pancreas is the fifth leading cause of cancer 
death in Western countries and it is estimated that only 1-4% of patients with pancreatic 
cancer will be alive for 5 years after diagnosis. This is largely attributable to difficulties 
in diagnosis, the progressive growth and metastasis even after extensive surgery, and 
the lack of effective systemic therapies (1). Effective treatment is not available and in 
most patients (more than 80%) surgical resection is not feasible.  
This tumor is less chemo-sensitive than other commonly occurring solid 
malignancies. Gemcitabine is a pyrimidine anti-metabolite (2). It is actively transported 
into the cells using specific transport systems such as the Equilibrative Nucleoside 
Transporter 1 (hENT1) protein. After metabolization, it is incorporated into DNA 
resulting in chain termination. Gemcitabine is active during S phase of the cell cycle 
against actively dividing cells and was approved for symptom management and 
prolonging survival in advanced pancreatic cancer (3).  
 
Metronomic chemotherapy is a novel and promising therapeutic strategy that 
involves regular administration of cytotoxic drug at doses that are low enough to avoid 
myelosuppression and other dose-limiting side effects that otherwise obligate rest 
periods. A number of pre-clinical studies have implicated angiogenesis blockade in the 
anti-tumor effects of metronomic chemotherapy (4). Metronomic chemotherapy 
continuously exposes the activated but slowly proliferating tumor endothelial cells to 
the damaging actions of the cytotoxic drug, thereby limiting their opportunity to repair 
and recover (5). In this context targeting of the growing neo-vasculature is believed to 
be responsible of the anti-tumor effect observed. The basis for this endothelial cell 
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selectivity and sensitivity is unknown. However, a possible clue was provided on the 
basis of gene (cDNA microarray) profiling studies undertaken on endothelial cells 
exposed to protracted low-dose chemotherapy drugs in vitro. A marked induction of 
thrombospondin 1 (TSP-1) a well known, highly specific and potent endogenous 
inhibitor of angiogenesis, was observed (6). 
 
In this article, we have aimed to investigate the anti-tumor effect of low-dose 
metronomic dosage of Gemcitabine in an orthotopic model of Gemcitabine-sensitive 
pancreatic carcinoma (NP18) and compare it to standard Gemcitabine administration. 
We have combined in vivo studies with in vitro experiments that evaluated the drug 
effect on the tumor and endothelial cells. Our results have shown that metronomic is as 
effective as conventional Gemcitabine administration and confirm that an anti-
angiogenic mechanism of action is involved.  
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MATERIAL AND METHODS 
 
IN VITRO STUDIES  
Cell culture 
 Human Umbilical Vein Endothelial Cells (HUVEC) were obtained from 
Advancell (Barcelona) and Cambrex (Baltimore), and were cultivated in M199 
(Biowhittaker) supplemented with 20% FCS, 50 U/ml penicillin, 50 µg/ml streptomycin 
sulphate, 150 µg/ml endothelial cell growth supplement, 100 µg/ml heparin, 2 mM 
sodium pyruvate, 1 mM Hepes pH 7.4.  
 Human Micro-Vessel Endothelial cells (HMEC-1), provided by Dra. Ofelia 
Martinez (UB, Barcelona), were maintained in MCDB 131 medium (Invitrogen) 
supplemented with 20% FCS, 50 U/ml penicillin, 50 µg/ml streptomycin sulphate, 10 
ng/ml epidermal growth factor (EGF), 1 µg/ml hydrocortisone, 2 mM sodium pyruvate, 
1mM Hepes pH 7.4. 
The p53 mutant NP18 cell line was derived from a poorly differentiated liver 
metastasis of a human adenocarcinoma of the pancreas which had been perpetuated as a 
xenograft in nude mice (7-9). NP18 cells were maintained in RPMI 1640 medium 
supplemented with 10% foetal bovine serum and penicillin (100 U/mL) and 
streptomycin (100 µg/mL). All cells were incubated in a humidified atmosphere 
containing 5% CO2 at 37ºC. 
 
Western blots 
 HUVEC or NP18 cells were washed twice in cold phosphate-buffered saline 
(PBS) and lysed for 15 min at 4°C in RIPA lysis buffer (0.1% SDS, 1% NP-40, 0.5% 
sodium deoxicholate, 50 mM NaF, 5 mM EDTA, 40 mM β-glycerophosphate, 200 µM 
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sodium orthovanadate, 100 µM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, 1 
µg/ml leupeptin, 4 µg/ml aprotinin). NP 18 tumors were lysed in laemmli sample buffer 
(62.5 mM Tris, 2% SDS, 10% glycerol, pH 6.8). Insoluble material was removed by 
centrifugation at 12000 X g for 5 minutes at 4ºC. Western blots were performed as 
described (10). The blots were incubated with polyclonal rabbit anti-PARP antibody 
(Cell Signaling), polyclonal anti-caspase-3 antibody (Cell Signaling), monoclonal anti-
caspase-9 antibody (Upstate), monoclonal anti-thrombospondin-1 antibody (Ab11, 
NeoMarkers, Fremont, CA, kindly provided by Dr. Mónica Feijoo, Madrid, 
Complutense University) or monoclonal anti-tubulin antibody (Sigma) in blocking 
solution overnight at 4°C.  
 
Cell viability assessment 
 HUVE cells were grown to 80% of confluence in a 24-well plate. They were 
harvested with M199 medium 0.5% FCS during 24 hours. Then, they were stimulated 
with M199 medium 10% FCS in the absence or presence of increasing concentrations of 
gemcitabine, and with 600 nM staurosporine. After 24 hours of incubation at 37ºC, dead 
cells were identified by staining with 0.4 µg/ml propidium iodide during 10 minutes at 
37ºC. The fluorescence images were captured with a Leica inverted phase-contrast 
microscope DMIRBE equipped with digital capture software. 
 
 [3H]Thymidine Incorporation Assay 
 HUVEC and HMEC-1 were seeded in 24-well plate. They were grown to 
confluence and then, they were harvested with M199 or MCDB 131 medium without 
FCS. After 24 hours, cells were stimulated with 10 ng/ml VEGF (Oncogene Research 
Products) in the absence or presence of increasing concentrations of gemcitabine and 
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with 1 µCi of [3H] thymidine ([6-3H]thymidine) (0.5 Ci/mmol, Amersham Pharmacia 
Biotech). NP18 cells were grown in 24-well in RPMI 1640 medium supplemented with 
10% fetal bovine serum for 24 hours. Thymidine incorporation was measured as 
described (10). 
 
IN VIVO STUDIES 
Orthotopic models  
NP18 is a pancreatic cancer cell line established from a poorly differentiated and 
metastatic adenocarcinoma of the pancreas, which have been previously perpetuated in 
our laboratory as xenografts in nude mice by orthotopic implantation (8, 9). Four week 
old male nu/nu Swiss mice weighing 20-25 g (Iffa-Credo Animaux de Laboratoire, 
L’Abresle, France) were used for tumor expansion. After sacrifice, thirty mg solid 
tumor fragments of human pancreatic NP18 xenografts were used for implantation at 
the pancreas (orthotopic implantation) of the distinct animals. Nude mice were 
anaesthetized with 2,2,2-tribromoethanol (Sigma-Aldrich). Implantation was performed 
anchoring tumor pieces with prolene 7.0 suture at the pancreas after left sub-costal 
incision. Incision was closed with staples or silk suture. All animal studies described 
were approved by the local committee for animal care. 
 
Drugs and Therapeutics Schedules 
Gemcitabine was purchased by Eli Lilly (Spain) and dissolved in buffered saline 
before administration. 
 
Dose-finding experiments: 
Standard dose: 
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Treatment with 100-120 mg/kg of Gemcitabine, injected four times at 3-day 
intervals (days 0, 3, 6 and 9 after implantation) was the more effective in all the 
reviewed studies (11-13) and was chosen as the standard dose.  
Metronomic dose: 
The pharmacokinetics of Gemcitabine has been examined following single 
parenteral doses of Gemcitabine hydrochloride in mice, rats, and dogs. The elimination 
of Gemcitabine is rapid in all species, with mean values for primary half-life ranging 
from approximately 0.3 hours in mice to 2.1 hours in rats (Lilly). We designed a small 
toxicity study, using immune-competent Swiss mice where Gemcitabine was 
administered intra-peritoneally (ip) in a daily schedule for a month, at increasing doses 
of 1 mg/kg, 2 mg/kg and 5 mg/kg (five animals per group). Mice were weighed twice 
per week. Animals were sacrificed 4 weeks after the first administration of the drug. At 
sacrifice, animals were bled from cardiac puncture and blood was collected for studying 
haematological parameters. Gemcitabine caused the death of all mice at 5 mg/kg. 
Deaths were attributed to adverse intestinal enteropathy. Histopathology of liver and 
kidney demonstrated hydropic degeneration and congestion respectively. No deaths 
were observed in the remaining groups. Dose-related clinical observations included 
rough hair, perineal soiling, and decreases in values of haematological parameters 
(hematocrit and platelets). All these side effects were minimal at 1 mg/kg. With this 
toxic good profile and the previous pre-clinical studies from Lilly, we chose 1 mg/kg as 
the “optimal” metronomic dose. 
 
Gemcitabine treatment starting on implantation day 
Standard Gemcitabine schedule: Xenografted animals were randomly distributed to 
control (n=13) and experimental (Gemcitabine) (n=13) groups. Four of the 26 animals 
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died -three belonging to the control group and one to the treatment group- within the 
first week after implantation. Death was attributed to the surgical procedure and mice 
were excluded from the analysis. Treatment began at the day of implantation using 
Gemcitabine 100 mg/kg ip on days 0, 3, 6 and 9. Control group received sham 
injections with vehicle alone (saline serum).  
Metronomic gemcitabine schedule: Once implanted, nu/nu Swiss mice were randomly 
distributed to control (n=15) and experimental group (n=15, low-dose Gemcitabine). 
One of the 30 animals died -belonging to the treatment group- within the first week after 
implantation. Death was attributed to the surgical procedure and mouse was excluded 
from the analysis. Treatment began at the day of implantation following Gemcitabine 
schedule: 1 mg /kg ip daily for a month. Control group received sham injections with 
vehicle alone (saline serum). Four weeks after implantation animals were sacrificed. 
Control of the animals and tumor processing was performed as described above.  
 
Gemcitabine treatment starting when tumor was established. 
Once implanted, forty nu/nu Swiss mice were randomly distributed to control (n=10; 
saline) and two experimental groups, one with low-dose Gemcitabine (n=15, 1 mg/Kg 
per day for one month) and the other group with “standard” Gemcitabine dose, as 
described above (n=15, 100 mg/Kg on days 0, 3, 6 and 9 assuming day 0 as the day of 
palpable tumor volume). In this experiment, in one of the forty mice there was no tumor 
growth. Two mice (one in the control group and one in the metronomic group) died of 
bowel obstruction after the surgical procedure and were excluded from the analysis. 
Treatment started when the tumor volume reached roughly 0.5-1cm3 (palpable tumor 
volume) occurring between day +8 and +18 post-implantation.  
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Time course experiment with gemcitabine treatment starting with established 
tumor  
Once NP18 tumours were palpable, twenty four nu/nu Swiss mice were randomly 
distributed to control (n=8; saline) and two experimental groups, one with metronomic 
schedule of Gemcitabine (n=8, 1 mg/Kg per day) and the other group with “standard” 
Gemcitabine dose (n=8; 100 mg/Kg on days 0, 3, 6 and 9 assuming the day 0 as the day 
of palpable tumor). Two time points, days 10 and 20 after initiation of treatment, were 
selected. Three animals were excluded from the analysis (1 post-surgical death and two 
animals with no apparent tumor growth). At each time point, 3 or 4 mice from each 
group were sacrificed and tumor processing was performed as described above. 
 
Immunofluorescence staining 
Five-micrometer-thick sections were used for CD31 (BD Pharmigen) (endothelial 
marker)/ Ki-67 (NeoMarker) double staining for quantification of micro-vessel density 
and proliferating cells respectively. Micro-vascular Density Average Vessel was 
quantified as the mean number of CD31 structures observed in 5 high power (40 x) 
fields of vision per tumor (central area); 4 independent tumors per experimental group 
were analyzed. Quantification of the CD31 staining area (µm2) was calculated using the 
Leica Confocal Sofware . 
 
Assessment of  human tumor VEGF levels and circulating mouse VEGF levels by 
Enzyme Immunoassay:  
Expression levels of human VEGF in tumor (given the human origin of the implanted 
tumor) were examined by ELISA following the manufacturer’s instructions (Quantikine 
Immunoassay Kits: R&D Systems). We examined lysed tumors from each treatment 
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group at each time point of the time course experiment. Circulating mouse plasma 
VEGF from the blood collected at the end of the experiment corresponding to each 
group of treatment (n=5 per each group), was also examined by ELISA. All experiments 
were repeated twice with at least two replicates per sample. 
 
Statistical Analysis 
We estimated the equal sample size for the study groups with the help of a statistical 
software (UCLA Department of Statistics http://calculators.stat.ucla.edu/powercalc). 
The study was designed to be able to detect a 0.35 difference in a continuous variable 
with 0.90 power and an alpha error of 0.05. Statistical analysis was carried out by SPSS 
packed program. Differences in tumours volume, weight  and VEGF levels were 
compared by the Mann-Whitney U test based on a two-tailed test. Kruskall-Wallis test 
was made for comparison between the three groups. P<0.05 was considered statistically 
significant. 
 
 
RESULTS 
 
In vitro results 
In order to evaluate a putative anti-angiogenic role of Gemcitabine, we 
performed in vitro experiments using endothelial cells in culture. We measured 
thymidine incorporation to DNA in HUVEC (primary cultures of endothelial cells from 
human umbilical vein) and HMEC-1 (immortalized endothelial cell line from human 
microvasculature) and compared with incorporation in NP18, a tumoral pancreatic cell 
line. Endothelial cells were harvested for 24 hours and incubated in the presence of 10 
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ng/ml VEGF (vascular endothelial growth factor) and different concentrations of 
Gemcitabine (from 5 nM to 500 nM) measuring thymidine incorporation for 24 hours. 
As observed in figure 1A, Gemcitabine caused a dose-response decrease of thymidine 
incorporation with a maximal inhibition obtained at 25 nM, and an IC50 of 3 nM. HUVE 
cells are a primary culture that under an incubation period without growth factors died. 
In order to rule out that the high sensitivity of endothelial cells to Gemcitabine was 
caused by harvesting, we repeated this experiment with exponentially growing HUVEC. 
In this condition results were comparable, with an IC50 for Gemcitabine of 3 nM (data 
not shown). In contrast, exponential growing NP18 cells presented an IC50 for 
Gemcitabine of 20 nM (Fig 1A). 
 To study a possible effect of Gemcitabine inducing apoptosis of endothelial 
cells, cell viability by staining dead cells with propidium iodide was measured in 
HUVEC cultures after an incubation of 24 hours with different gemcitabine 
concentrations (Fig. 1B). Apoptosis was only observed at high doses of Gemcitabine 
(500 nM), but not at low doses of Gemcitabine when proliferation was already affected. 
We observed apoptosis at low Gemcitabine doses only when the drug was added for at 
least 48 h (data not shown). To confirm these results, we examined by Western Blot 
activation of a typical apoptotic signaling pathway (active caspase-3 and -9 and PARP 
cleavage). Only gemcitabine at high doses was associated with a slight activation of 
caspase-3 activity (Fig. 1C). 
 
 
In vivo results 
Given the high sensitivity of endothelial cells to gemcitabine, next we analyzed 
the effect of this drug on a xenograft pancreatic carcinoma (NP18) growth using a 
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putative in vivo anti-angiogenic administration schedule, the metronomic dosing. After 
a toxicity study (Table 1, described in Material and methods section) a metronomic dose 
of 1 mg/kg/day was chosen and compared it with the standard schedule.  
 
Gemcitabine treatment starting on implantation day  
Using the conventional mice dosing gemcitabine significantly inhibited NP18 
local tumor weight and volume (Fig 2A). No distal metastases were observed in control 
and standard gemcitabine treated groups. No significant differences were observed 
regarding mice weight gain between both groups: 5 g for standard Gemcitabine versus 7 
g in the control group (p=0.44). 
Using the optimal metronomic dose similar results were obtained, observing a 
significant reduction in tumor weight and volume (Fig 2B). Using this schedule the 
mice weight gain rate was significantly diminished in the metronomic Gemcitabine 
group: 3.9 g. in metronomic Gemcitabine versus 5.9 g in the control group (p= 0.026). 
 
Gemcitabine treatment starting when NP18 tumours were established.  
Given the results obtained, next we assayed if metronomic schedule was also 
effective blocking growth of NP18 established tumor. We observed that both standard 
and metronomic schedules similarly inhibited tumor growth compared to the control 
group (Fig. 3A). No distal metastases were observed in control or treated groups.  
In this setting, no significant differences were observed regarding mice weight 
between the control, standard and metronomic groups. Thus, the diminished mice 
weight gain observed in the first experimental setting can be attributed to the combined 
stress of the surgical procedure and the immediate initiation of Gemcitabine treatment. 
 
 14
NP18 time course and tumor micro-vessel study 
In order to better analyse the relative contribution of the anti-tumoral and anti-
angiogenic action of gemcitabine, we performed a time-course with established NP18 
tumours. As shown in Figure 3B and C, no differences in tumor growth between 
treated and control groups were observed at day 10 of treatment. This tendency changed 
dramatically at the second time point (20 days of treatment), where a greater and 
significant anti-tumoral effect was observed in experimental groups compared with 
saline group. Differences were significant between metronomic and control (p=0.034) 
and close to significance between standard and control groups (p=0.05). In spite of the 
fact that median tumor volume in the metronomic group was usually half of the 
standard treatment group, differences observed among treated groups did not reach 
statistical significance (p=0.29) (Fig 4A). Thus we conclude that metronomic 
Gemcitabine blocked tumor growth as effectively as the standard Gemcitabine schedule 
being this action evident at day 20 after the initiation of treatment. 
The time course experiment performed, with and earlier (10 days of treatment) 
and medium time points (20 days of treatment), allowed us to study more deeply the 
tumor histology and by immune-fluorescence staining the vessels patterns of the three 
groups. Macroscopically, at day 20 we found that control tumours were more vascular 
than treated ones, as Fig 4A shows. Microscopically, while great vessels forming 
tubular structures were apparent in control group, only isolated endothelial cells were 
observed in both treated groups (Fig. 4B). While no differences in the number of 
vessels were observed among the two treated groups, a marked and significant decrease 
in CD31 staining area was observed at day 20 in metronomic treated tumors (Fig. 4C), 
suggesting that vascular structures were altered by metronomic gemcitabine treatment.  
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Assessment of human and mouse VEGF and thrombospondin-1 levels 
 To explore the association between the anti-angiogenic effect suggested by 
inmunofluorescence in the metronomic group and a putative molecular mechanism of 
action, first we explored a possible effect of gemcitabine on VEGF expression. We 
measured human VEGF levels from tumor samples collected at each time point in the 
time course experiment. For both explored time points there were no differences in 
tumor VEGF median levels between the three groups (data not shown). In addition, no 
differences were observed in circulating mouse VEGF levels at the end of the 
experiment with gemcitabine starting when NP 18 tumor was established (five mice per 
each group): metronomic group 58 pg/µl (range 52-64), 66.5 pg/µl (range 58-82) in 
standard gemcitabine group and 63 pg/µl (range 58-93) in control group. 
 Finally we explored the role of thrombospondin-1 (TSP-1) on the metronomic 
effect of gemcitabine. We measured TSP-1 protein levels in the three groups of 
established tumors treated with saline, standard or metronomic gemcitabine for 10 and 
20 days. At day 10, metronomic gemcitabine was associated with high TSP1 protein 
levels that decreased at day 20 (Fig. 5A and data not shown). In order to identify the 
origin of TSP-1, we performed additional in vitro experiments treating HUVEC and 
NP18 cells with gemcitabine for 24 h and measured TSP-1 protein levels by western 
blot. As we show in Fig. 5B, increased TSP-1 levels were observed in treated HUVEC 
without any effect on NP18. 
 
 
DISCUSSION 
In the present study we have shown that the anti-tumor efficacy with 
metronomic low dose Gemcitabine schedule is equivalent to that of conventional dosing 
 16
in an orthotopic model of human pancreatic carcinoma. Our in vitro and in vivo studies 
point to a combined cytotoxic action on tumor cells and cytostatic action on endothelial 
cells.  
Low-dose metronomic chemotherapy is a promising therapeutic cancer strategy 
thought to have an anti-angiogenic basis (5) (14). It involves the regular administration 
of cytotoxic drugs at doses low enough to avoid myelosuppression and other dose-
limiting side effects that otherwise obligate rest period. Although a number of 
alternative schedules and chemotherapy combinations of gemcitabine have been 
evaluated (11, 15-17), no attempt has been made to explore a low-dose well-tolerated 
administration schedule for gemcitabine in preclinical models of pancreatic carcinoma. 
This is especially needed when metronomic-like scheduling of Gemcitabine has been 
initially evaluated in the clinical setting with encouraging results (18, 19) and its 
putative efficacy has to be tested in phase III clinical trials. 
Our results indicate that, at total doses that are 12 times lower than the 
conventional gemcitabine mice schedule, metronomic Gemcitabine showed the same 
efficacy observed with the conventional schedule, in the absence of toxic effects. 
Gemcitabine not only was effective inhibiting tumor growth when administered 
immediately after tumor implantation, but in exponentially growing tumors as well. The 
latter results suggest that gemcitabine may be active in the proliferating tumor vessels. 
More experiments need to be performed to confirm or discard this hypothesis.  
The corresponding tumor cell line NP18 is sensitive to gemcitabine at doses [our 
present results and (7)] that are well below the previously reported peak plasma 
concentration (100 µM) of gemcitabine at maximum tolerated dose (17). These results 
suggest that following a metronomic schedule, gemcitabine may have an anti-tumor 
effect. Sensitivity of human pancreatic tumor cell lines derived from primary or 
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metastatic pancreatic tumours has been previously explored (13, 20-26). Some of these 
cell lines are sensitive to gemcitabine at similar doses that we use, suggesting that our 
findings may be relevant to a significant subset of pancreatic tumors.  
A number of pre-clinical studies have implicated angiogenesis blockade in 
metronomic anti-tumor effects, where targeting of the growing neo-vasculature led to a 
secondary anti-tumor effect. Human endothelial cells of normal and tumor vasculature 
express hENT-1, the nucleotide transporter for gemcitabine, necessary to exert its 
putative cytostatic action (27). On the other hand, several studies have been undertaken 
to test the anti-proliferative, migration-inhibitory and sometimes cytotoxic effects of 
pico-molar concentrations of chemotherapeutic drugs on various human cell types, 
including micro-vascular or macro-vascular endothelial cells (4, 28, 29). Initially, 
cyclophosphamide, when administered at metronomic (one third of the MTD) schedule, 
showed impressive anti-angiogenic and anti-tumor effects on mice tumor cell lines 
subcutaneously grown in the syngenic mice. A detailed temporal analysis showed that 
endothelial cells were the first cell type within the tumor to undergo apoptosis (4). Other 
studies have shown similar effect of various microtubule inhibitors, such as vinblastine, 
paclitaxel and docetaxel (28, 30-33). In these experiments, ultra-low concentrations of 
these drugs were reported to inhibit proliferation or migration of endothelial cells. In 
our study, gemcitabine induces cell-cycle arrest in human endothelial cells in line with 
previous reports (34). Interestingly, gemcitabine did not affect their ability to induce in 
vitro tubular structures (data not shown), suggesting a lack of effect on endothelial cell 
migration.  
Concerning in vivo experiments, the time course experiment performed allowed 
us to study more deeply the tumor histology and, by immune-fluorescence staining, the 
vessels patterns of the three groups. Differences in CD31 staining area indicate a clear 
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effect of gemcitabine on the architecture of vascular structures, decreasing the number 
of tubular vessels and increasing the number of isolated and non structured endothelial 
cells. These results confirm the previous in vitro observation of gemcitabine on 
endothelial cells. Moreover, this effect is enhanced by metronomic administration of the 
drug, supporting anti-angiogenesis as a relevant mechanism of action of metronomy. 
 
Thrombospondin 1 (TSP-1), a component of the extracellular matrix that can 
also be secreted and found in the circulation, is a well known endogenous inhibitor of 
angiogenesis (35). In our model system, TSP-1 protein induction might provide an 
explanation for the specificity of the effects of metronomic chemotherapy treatment. In 
addition to or perhaps even instead of a direct anti-proliferative or cytotoxic anti-
endothelial cell effect TSP-1 may be the potential mediator of the effects of metronomic 
chemotherapy (6, 36). In a previous study, 5 days of exposure to low concentrations of 
various chemotherapeutic drugs caused a marked increase in TSP-1 mRNA and protein 
levels in vascular endothelial cells in vitro (other cells were not tested) (6). In our 
experimental system, NP18 cells in culture express low levels of TSP1 even after 
gemcitabine treatment; in contrast, HUVEC treated with gemcitabine express increased 
TSP-1 protein levels supporting the vascular origin of TSP-1 in our xenograft pancreatic 
carcinoma model. This hypothesis could explain the decrease in TSP-1 levels in 20 days 
metronomic treated tumors, when vascular structures were clearly affected. Future 
studies will help us to confirm or discard this hypothesis.  
TSP-1 can also bind and sequester VEGF, and therefore block its pro-angiogenic 
activity (37). In our work, we could not show a variation in human tumor VEGF 
expression between groups but we found a diminished circulating mouse plasma VEGF 
level in metronomic group comparing with standard group, although this difference was 
 19
not statistically significant. In this regard, Colleoni et al. have reported that serum 
VEGF levels declined in patients who responded to metronomic therapy (38). 
Altogether, our results are consistent with the evidence, mostly in vitro, 
indicating that the "activated" endothelial cells of newly forming blood-vessel 
capillaries are highly sensitive to very low doses of various chemotherapeutic drugs. 
While it has been postulated that this effect is due to a limited ability to repair the 
induced damage, this issue remains largely unknown. 
 
Some promising preliminary results have begun to emerge in small clinical 
studies using mostly orally administered metronomic chemotherapy–based regimens 
(38-41), including those in the adjuvant setting for early-stage cancer. A recent 
prospective randomized study by Sakamoto et al. comparing a low-dose Gemcitabine 
regimen and standard-dose regimen in pancreatic adenocarcinoma patients, showed a 
reduced toxicity and an improved safety profile without survival differences between 
groups (19). Moreover, Takahashi et al describe a metronomic-like weekly dosing of 
Gemcitabine in metastatic pancreatic cancer looking for an optimal biological and 
nontoxic dose of Gemcitabine (18). However, these results clearly need to be supported 
by pre-clinical studies and validated in well designed prospective randomized phase III 
clinical trials. Our results (both, in vivo using an orthotopic pancreatic model and in 
vitro using human endothelial cells) are an additional argument to continue exploring 
alternative Gemcitabine administration schedules in pancreatic cancer patients, such as 
a low-dose regimen based on an additional anti-angiogenic mechanism of action. 
In summary, our study emphasizes that exploration of the anti-angiogenic and 
anti-tumor effects of metronomic chemotherapy in pre-clinical animal models is an 
important part in the continuous quest of developing regimens that can be used in the 
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clinic. Clearly, more pre-clinical studies are needed in order to elucidate drug-specific 
features and to optimize the metronomic dose and treatment schedule in different 
animals’ models of different tumor types. 
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FIGURE LEGENDS 
 
FIG. 1 In vitro gemcitabine effect on endothelial cell proliferation and apoptosis. 
A) Thymidine incorporation measured in the absence or presence of the indicated 
concentrations of gemcitabine for 24 h in HUVEC and HMEC-1 stimulated with VEGF 
(10 ng/ml) and NP18 in the presence of FCS (10%). Results are an average of three 
different experiments. 
B) Immunofluorescence microscopy of depleted HUVEC stimulated with 10% FCS in 
the absence or presence of the indicated concentrations of gemcitabine for 24 h. 
Staurosporine was used as positive control of apoptosis. 
C) HUVEC incubated as in B) were lysed and PARP, inactive caspase-9, active 
caspase-3 and tubulin (as a loading control) were detected by immunobloting. 
 
 
FIG.2 Gemcitabine treatment starting on implantation day. 
A) Tumor volume median in standard Gemcitabine group after a month of treatment 
was 0.007 cm3 (range 0-0.028) versus 0.29 cm3  in control group (range 0.079-2.28) (M= 
Median) (p<0.001); tumor weight median Gemcitabine 0.014 g (range 0- 0.035) versus 
control 0.39 g (range 0.12-1.7) (p<0.001). 
B) Tumor volume median in metronomic Gemcitabine group after a month of daily 
treatment was of 0.007 cm3 (range 0-0.5) versus 0.28 cm3 in control group (range 0.01-
1.06). (p<0.001). Tumour weight in gemcitabine treated was 0.009 g (range 0-0.31) 
versus 0.4 g (range 0.03-1.81) in the control group (p<0.001). 
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FIG. 3 Gemcitabine treatment starting with established tumor and time course. 
A) At day 28 both treated groups were better than control group as figure 2 represents 
(Kruskall-Wallis Test P<0.001). Data corresponded to the medians of the three groups 
(Median in metronomic group 0 cm3, range 0-0.03, M 0.003 in standard group with 
range 0-0.63 and M 2.35 in control group, range 0.01-4.73). Tumor weight was 0 g 
(range 0-0.3) in metronomic vs 0.01 g (range 0-0.59) in standard gemcitabine vs 1.8 g 
(range 0.07-3.28) in control group (p<0.001). Metronomic gemcitabine administration 
significantly inhibited tumor growth, compared with standard gemcitabine group 
(p=0.01), although these results reflect the same biological effect. 
 
B) Time course effect: We did not find significant differences concerning tumor volume 
between three groups at day 10. Data corresponded to the medians of the three groups 
(Median in metronomic group 0.53 cm3, range 0.38-0.68, M 0.44 in standard group 
with range 0.39-0.60 and M 0.69 in control group, range 0.49-1.07). We observed 
greater and significant anti-tumoral effect in metronomic and standard groups 
comparing with saline group (p=0.034 and p=0.05 -respectively) at day 20. Data 
corresponded to the medians of the three groups (Median in metronomic group 0.25 
cm3, range 0.11-0.67, M 0.51 in standard group with range 0.19-0.94 and M 1.1 in 
control group, range 1.05-3.11). 
C) Representation of the median tumor volume values at days 10, 20 of treatment and at 
the end of the experiment (day 28 of treatment). 
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Fig.4 In vivo anti-angiogenic effect of gemcitabine 
A) Representative images of macroscopic aspect of NP18 pancreatic tumor at 2nd time 
point (20 days of treatment). 
B) Immunofluorescence expression of CD31 on endothelial cells (red), Ki67 nuclear 
antigen (proliferation marker, green) in the three groups after 20 days of treatment.  
C) Median CD31 area values (µm2) from five fields (40x) of vision per tumor from four 
different mice belonging to the three groups of treatment.  
 
 
Fig. 5. Effect of gemcitabine on Thrombospodin-1 protein levels in tumors and cell 
cultures 
A) Thrombospondin-1 (TSP-1) and tubulin (as a loading control) were measured by 
immunobloting from lysates from established control tumors (C), and from established 
treated tumors following the standard (S) and metronomic schedule (M) for 10 days. 
Two independent tumors for every treatment are shown. 
Quantification of TSP-1 protein levels measured by western blot at day 10 corriged by 
tubulin levels. Mean of two independent tumors is showed. 
B) HUVEC and NP18 cells were treated with gemcitabine IC50 doses (3 nM and 20 nM 
respectively) for 24 h. After lysis, TSP-1 protein levels were measured by western blot, 
quantified by densitometry and corriged by tubulin levels. Mean of two independent 
experiments is showed. 
 
